Tags

Type your tag names separated by a space and hit enter

[Microbial antagonism and rationale for the use of probiotics in combined therapy of Helicobacter pylori-related diseases].
Klin Med (Mosk) 2010; 88(4):35-42KM

Abstract

This review discusses methods of Helicobacter pylori (HP) eradication, causes and consequences of its steadily growing resistance to therapy recommended by Maastricht Consensus (2005) and alternative treatment schemes including "reserved" antibacterial preparations. Different approaches to the solution of this problem are recommended, such as the use of phenomenon of microbial antagonism between endosymbiotic microorgnisms (bifido- and lactobacteria) and opportunistic and pathogenic microflora, e.g. cytotoxic HP strains. The data are presented on the mechanisms of antimicrobial action of bifido- and lactobacteria, pathogenic activity of different HP cytotoxic strains, normal and pathological microbiocenosis of the stomach. Prospects for the use of antibiotics containing bifido- and lactobacteria for the treatment of HP-related conditions are discussed.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

rus

PubMed ID

20919568

Citation

Tsimmerman, Ia S., et al. "[Microbial Antagonism and Rationale for the Use of Probiotics in Combined Therapy of Helicobacter Pylori-related Diseases]." Klinicheskaia Meditsina, vol. 88, no. 4, 2010, pp. 35-42.
Tsimmerman IaS, Subbotina LV, Neschisliaev VA. [Microbial antagonism and rationale for the use of probiotics in combined therapy of Helicobacter pylori-related diseases]. Klin Med (Mosk). 2010;88(4):35-42.
Tsimmerman, I. a. S., Subbotina, L. V., & Neschisliaev, V. A. (2010). [Microbial antagonism and rationale for the use of probiotics in combined therapy of Helicobacter pylori-related diseases]. Klinicheskaia Meditsina, 88(4), pp. 35-42.
Tsimmerman IaS, Subbotina LV, Neschisliaev VA. [Microbial Antagonism and Rationale for the Use of Probiotics in Combined Therapy of Helicobacter Pylori-related Diseases]. Klin Med (Mosk). 2010;88(4):35-42. PubMed PMID: 20919568.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Microbial antagonism and rationale for the use of probiotics in combined therapy of Helicobacter pylori-related diseases]. AU - Tsimmerman,Ia S, AU - Subbotina,L V, AU - Neschisliaev,V A, PY - 2010/10/6/entrez PY - 2010/10/6/pubmed PY - 2010/12/31/medline SP - 35 EP - 42 JF - Klinicheskaia meditsina JO - Klin Med (Mosk) VL - 88 IS - 4 N2 - This review discusses methods of Helicobacter pylori (HP) eradication, causes and consequences of its steadily growing resistance to therapy recommended by Maastricht Consensus (2005) and alternative treatment schemes including "reserved" antibacterial preparations. Different approaches to the solution of this problem are recommended, such as the use of phenomenon of microbial antagonism between endosymbiotic microorgnisms (bifido- and lactobacteria) and opportunistic and pathogenic microflora, e.g. cytotoxic HP strains. The data are presented on the mechanisms of antimicrobial action of bifido- and lactobacteria, pathogenic activity of different HP cytotoxic strains, normal and pathological microbiocenosis of the stomach. Prospects for the use of antibiotics containing bifido- and lactobacteria for the treatment of HP-related conditions are discussed. SN - 0023-2149 UR - https://www.unboundmedicine.com/medline/citation/20919568/[Microbial_antagonism_and_rationale_for_the_use_of_probiotics_in_combined_therapy_of_Helicobacter_pylori_related_diseases]_ L2 - https://medlineplus.gov/helicobacterpyloriinfections.html DB - PRIME DP - Unbound Medicine ER -